Event context and recent share performance

McKesson (MCK) stock has drawn attention after a mixed stretch for investors, with the share price up about 2.5% over the past day and roughly 4% over the past week.

That short burst of strength comes after a weaker stretch, with the share price down about 16% over the past 90 days and roughly 6% year to date, even as the 1 year and 5 year total shareholder returns remain positive and very large. This suggests recent moves may reflect shifts in sentiment or risk perceptions rather than a simple change in the long term story.

If this kind of move has you looking beyond McKesson, it could be a useful moment to broaden your search with our screener of 39 healthcare AI stocks

With McKesson stock still down over the past quarter, yet supported by solid recent revenue and net income growth, the key question is whether today’s US$775.66 price offers value or if the market already reflects future growth.

Price-to-earnings of 19.6x: Is it justified?

At a last close of $775.66, McKesson trades on a P/E of 19.6x, which screens as good value compared with both its own fair P/E estimate and healthcare peers.

The P/E ratio compares the share price with earnings per share, so it gives a quick sense of how much investors are paying for each dollar of profit. For a large, established healthcare services company with positive earnings and high quality earnings, this is a common yardstick for how the market is weighing current profits against expected future performance.

Here, McKesson’s 19.6x P/E is below the estimated fair P/E of 27.3x. This gap suggests the market price is not fully reflecting the level our fair ratio model indicates the stock could trade toward if sentiment and fundamentals stayed aligned. It also sits below the peer average of 22.9x and the broader US Healthcare industry average of 23.8x, which reinforces the idea that investors are currently paying less per dollar of earnings than they pay for comparable stocks in the sector.

Result: Price-to-earnings of 19.6x (UNDERVALUED).

However, you still need to weigh risks, including potential pricing pressure across large distribution contracts, as well as any slowdown in McKesson’s recent revenue and net income growth.

Another view: what our DCF model says

While the P/E work suggests McKesson could be trading below what the fair ratio points to, the SWS DCF model paints a very different picture. On this view, the stock at $775.66 sits far above an estimated future cash flow value of about $1.67, which flags clear valuation risk rather than opportunity. For you as an investor, it raises the question of which story you trust more: the earnings multiple or the cash flow math.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out McKesson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals feels conflicting, that is the point. Move quickly, review the numbers yourself, and carefully weigh both the potential upside and the areas of concern highlighted in 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If McKesson has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot other stocks that could fit your portfolio.

• Target potential mispricings by reviewing our list of 49 high quality undervalued stocks that combine quality with appealing valuations.
• Strengthen your income stream by assessing companies in the 9 dividend fortresses that offer higher yields with a focus on stability.
• Reduce portfolio surprises by filtering for 64 resilient stocks with low risk scores that score well on resilience and financial risk measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.